Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-006 in Advanced Solid Tumors
NCT07807345Phase 1Recruiting
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of STRO-006 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and 5 more (3 arms), sponsored by Sutro Biopharma, Inc. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 21 days and 5 more. Started Oct 2026; status: recruiting.
02
Drugs
STRO-006
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07807345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807345.